Mainstay Medical | Evaluate

Attempts to treat pain with non-opioid drugs have ended in repeated failures – but device makers have met with greater success.

Private device makers enjoy the biggest quarter for four years – and the average deal is larger than ever.

July 16, 2020

The pandemic prompts only a slight drop in medtech approvals.

November 19, 2018

Mainstay Medical still hopes for US approval of its Reactiv8 device for chronic back pain despite trial failure.

April 15, 2015

May 08, 2014

Evaluate